Drug intelligence / Profile preview

Adybrex

Development stage: Unknown
Lead developer: Adwya
Modality: Small Molecules
Administration: Oral

Overview

Adybrex is a branded generic formulation of celecoxib developed and marketed by the Tunisian pharmaceutical company Adwya. It is a selective cyclooxygenase-2 (COX-2) inhibitor indicated for the acute and chronic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal pain, as well as for managing acute post-operative pain. By selectively targeting COX-2, Adybrex inhibits prostaglandin synthesis to provide anti-inflammatory and analgesic effects while minimizing the gastrointestinal risks typically associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) that also inhibit COX-1.

Brand names: Adybrex

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Adybrex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adybrex.

Explore the full profile